secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0000950170-22-026089
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

RT-102 repeat-dose Phase 1 meets endpoints; 91% delivery success, high bioavailability, supports Phase 2
--------------------------------------------------------------------------------

- No serious adverse events; all 10 participants completed 7-day daily dosing.
- RaniPill GO delivered PTH with 91% overall success; Day 7 success rate 100%.
- RT-102 showed high PTH bioavailability vs subcutaneous injection in Part 1.
- Company expects to initiate Phase 2 trial of RT-102 in osteoporosis in H2 2023.
- Over 185 RaniPill capsules administered in clinical studies; platform advancing for multiple programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017022026089/0000950170-22-026089-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017022026089/rani-20221206.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026089

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer